Tag: repurchase

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Logan Ridge Finance Corporation (NASDAQ: LRFC) (“Logan Ridge” or “LRFC”) announced today that it obtained shareholder approval for the merger of LRFC with and into Portman Ridge Finance Corporation (NASDAQ: PTMN) (“Portman Ridge” or “PTMN”) following the special meeting of shareholders held on June 20, 2025.

Transaction in Own Shares

COMPAGNIE DE L'ODET

REMARKABLY PRESERVED 1962 SHELBY 260 COBRA, ONE OF THE ORIGINAL PROTOTYPE EXAMPLES, OFFERED FROM 36 YEARS OF CHERISHED LONGTERM OWNERSHIP | COBRA JOINED BY MODERN AMERICAN AUTOMOTIVE LEGENDS: HENNESSEY VENOM GT AND THE AMERICAN PERFORMANCE COLLECTION OF DODGE AND CHEVROLET ICONS

Press release
Paris, 20 June 2025

Transaction in Own Shares

WAUSAU, Wis., June 18, 2025 (GLOBE NEWSWIRE) -- PSB Holdings, Inc. (OTCQX: PSBQ), parent company of Peoples State Bank, is pleased to announce that on June 17, 2025, its Board of Directors declared a regular semi-annual cash dividend of $0.34 per share of the Company’s common stock. The dividend is payable July 31, 2025 to shareholders of record as of July 11, 2025 and represents an increase of 6.3% over the $0.32 per share semi-annual cash dividend declared on December 17, 2024. The current dividend continues a 60-year tradition of cash dividends to PSB shareholders including 32 consecutive years of increased cash dividends declared per share.

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Verizon Communications Inc. (“Verizon”) (NYSE, Nasdaq: VZ) today announced the pricing terms of its two previously announced related transactions to repurchase 10 series of its outstanding notes listed in the tables below.

CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia (FA) between the ages of 2 to <16. Both non-ambulatory and ambulatory participants may qualify for the study. Participants will be randomized 2:1 to receive omaveloxolone or placebo once a day for 52 weeks before having the opportunity to move into the open-label extension (OLE). Currently, omaveloxolone is commercialized under the brand name SKYCLARYS^® in over 40 countries, including in the U.S. and the European Union, and is the only approved product for FA in adults and adolescents aged 16 years and older.